Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Arcturus Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$92.43M. For fiscal 2025 it was -$73.24M. The highest annual figure on record is $13.70M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$73.24M | – |
| FY2024 | Dec 31, 2024 | -$92.13M | – |
| FY2023 | Dec 31, 2023 | -$75.25M | -649.1% |
| FY2022 | Dec 31, 2022 | $13.70M | – |
| FY2021 | Dec 31, 2021 | -$201.66M | – |
| FY2020 | Dec 31, 2020 | -$70.64M | – |
| FY2019 | Dec 31, 2019 | -$24.83M | – |
| FY2018 | Dec 31, 2018 | -$21.23M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$8.59M | – |
| Q2 FY2026 | Jun 30, 2026 | -$24.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$28.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.51M | -292.4% |
| Q4 FY2023 | Dec 31, 2023 | -$17.46M | -114.3% |
| Q3 FY2023 | Sep 30, 2023 | -$18.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$54.67M | – |
| Q1 FY2023 | Mar 31, 2023 | $15.33M | – |
| Q4 FY2022 | Dec 31, 2022 | $122.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$36.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$50.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$53.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$53.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$57.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.81M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.74M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.28M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$372.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.34M | – |
| Q4 FY2018 | Dec 31, 2018 | -$544.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.97M | – |
See a number that looks wrong?